Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma

International Journal of Biological Markers

Volumn 22, Issue 4, 2007, Pages 302-306

  Mattioni, Manlio ^a   Soddu, S ^a   Porrello, A ^a   D'Alessandro, R ^b   Spila, A ^b   Guadagni, F ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Gastric cancer; Mutant p53; Prognosis; Serum anti p53 antibodies

Indexed keywords

PROTEIN ANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK FACTOR; STOMACH BIOPSY; STOMACH CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

EID: 39149106014     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.1415     Document Type: Article

References (20)

1. Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60: 1777-88.
2. Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN, Wang L. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res Treat 2005; 93: 111-5.
3. Lenner P, Wiklund F, Emdin SO, et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer 1999; 79: 927-32.
4. Shiota G, Ishida M, Noguchi N, et al. Circulating p53 antibody in patients with colorectal cancer. Relation to clinicopathologic features and survival. Dig Dis Sci 2000; 45: 122-8.
5. Chang SC, Lin JK, Lin TC, Liang WY. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol 2005; 26: 65-75.
6. Mack U, Ukena D, Montenarh M, Sybrecht GW. Serum anti-p53 antibodies in patients with lung cancer. Oncol Rep 2000; 7: 669-74.
7. Bergqvist M, Brattstrom D, Larsson A, et al. p53 autoantibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Anticancer Res 1998; 18: 1999-2002.
8. Murray PV, Soussi T, O'Brien MER, et al. Serum p53 antibodies: predictors of survival in small cell lung cancer? Br J Cancer 2000; 83: 1418-24.
9. Zalcman G, Tredaniel J, Schlichtholz B, et al. Prognostic significance of serum p53 antibodies in patients with limited stage small cell lung cancer. Int J Cancer 2000; 89: 81-6.
10. Bergqvist M, Brattstrom D, Lamberg K, et al. The presence of anti-p53 antibodies in sera prior to thoracic surgery in non small cell lung cancer patients: its implications on tumor volume, nodal involvement, and survival. Neoplasia 2003; 5: 283-7.
11. Jassem E, Bigda J, Dziadziuszko R, et al. Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance. Lung Cancer 2001; 31: 17-23.
12. Maehara Y, Kakeji Y, Watanabe A, et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer 1999; 85: 302-8.
13. Wu CW, Lin YY, Chen GD, Chi CW, Carbone DP, Chen JY. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer 1999; 80: 483-8.
14. Wurl P, Weigmann F, Meye A, et al. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand J Gastroenterol 1997; 32: 1147-51.
15. Shimizu K, Ueda Y, Yamagishi H. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer 2005; 8: 214-9.
16. Saffroy R, Lelong JC, Azoulay D, et al. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 1999; 79: 604-10.
17. Goodell V, Salazar LG, Urban N, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006; 24: 762-8.
18. Lubin R, Schlichtholz B, Teillaud JL, et al. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1995; 1: 1463-9.
19. Sangrajrang S, Sornprom A, Chernrungroj G, Soussi T. Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. Lung Cancer 2003; 39: 297-301.
20. Volkmann M, Sinn HP, Gaugel D, et al. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology 2002; 63: 297-305.